WRBY Quote, Financials, Valuation and Earnings

Daxor Corp. has a net margin of -2.81% compared to Warby Parker, Inc.'s net margin of --. Warby Parker, Inc.'s return on equity of 0.46% beat Daxor Corp.'s return on equity of 1.57%.

Warby Parker, Inc. has a consensus price target of $28.67, signalling upside risk potential of 13.29%. On the other hand Daxor Corp. has an analysts' consensus of $22.50 which suggests that it could grow by 89.71%. Given that Daxor Corp. has higher upside potential than Warby Parker, Inc., analysts believe Daxor Corp. is more attractive than Warby Parker, Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daxor Corp. has a beta of 0.048, suggesting its less volatile than the S&P 500 by 95.223%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Daxor Corp. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $212M, which are larger than Daxor Corp. quarterly revenues of --. Warby Parker, Inc.'s net income of -$6M is higher than Daxor Corp.'s net income of --. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 2,066.94x while Daxor Corp.'s PE ratio is 40.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 3.56x versus 54.99x for Daxor Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics Corp., Inc. has a net margin of -2.81% compared to Warby Parker, Inc.'s net margin of -24.17%. Warby Parker, Inc.'s return on equity of 0.46% beat Precision Optics Corp., Inc.'s return on equity of -62.69%.

Warby Parker, Inc. has a consensus price target of $28.67, signalling upside risk potential of 13.29%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Warby Parker, Inc. has higher upside potential than Precision Optics Corp., Inc., analysts believe Warby Parker, Inc. is more attractive than Precision Optics Corp., Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.623%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $212M, which are larger than Precision Optics Corp., Inc. quarterly revenues of $7.4M. Warby Parker, Inc.'s net income of -$6M is lower than Precision Optics Corp., Inc.'s net income of -$1.8M. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 2,066.94x while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 3.56x versus 1.32x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -2.81% compared to Warby Parker, Inc.'s net margin of -316.61%. Warby Parker, Inc.'s return on equity of 0.46% beat Plus Therapeutics, Inc.'s return on equity of --.

Warby Parker, Inc. has a consensus price target of $28.67, signalling upside risk potential of 13.29%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Warby Parker, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Warby Parker, Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $212M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Warby Parker, Inc.'s net income of -$6M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 2,066.94x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 3.56x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech, Inc. has a net margin of -2.81% compared to Warby Parker, Inc.'s net margin of 3.17%. Warby Parker, Inc.'s return on equity of 0.46% beat Sanara MedTech, Inc.'s return on equity of -20.48%.

Warby Parker, Inc. has a consensus price target of $28.67, signalling upside risk potential of 13.29%. On the other hand Sanara MedTech, Inc. has an analysts' consensus of $40.00 which suggests that it could grow by 95.7%. Given that Sanara MedTech, Inc. has higher upside potential than Warby Parker, Inc., analysts believe Sanara MedTech, Inc. is more attractive than Warby Parker, Inc..

Warby Parker, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanara MedTech, Inc. has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.68%.

Warby Parker, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Warby Parker, Inc. pays -- of its earnings as a dividend. Sanara MedTech, Inc. pays out -- of its earnings as a dividend.

Warby Parker, Inc. quarterly revenues are $212M, which are larger than Sanara MedTech, Inc. quarterly revenues of $26.3M. Warby Parker, Inc.'s net income of -$6M is lower than Sanara MedTech, Inc.'s net income of $834.5K. Notably, Warby Parker, Inc.'s price-to-earnings ratio is 2,066.94x while Sanara MedTech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Warby Parker, Inc. is 3.56x versus 1.72x for Sanara MedTech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.